Ryvu

What Ryvu does

Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical company headquartered in Kraków, Poland, founded in 2007 (formerly Selvita S.A.) and listed on the Warsaw Stock Exchange under ticker RVU. It develops first-in-class small molecule therapies addressing emerging oncology targets, with a portfolio led by romaciclib (RVU120/SEL120), an oral CDK8/19 inhibitor in Phase II for relapsed/refractory acute myeloid leukemia (RIVER-81), myelofibrosis (POTAMI-61) and low-risk MDS (REMARK), and dapolsertib (MEN1703/SEL24), a dual PIM/FLT3 inhibitor in Phase II for diffuse large B-cell lymphoma (JASPIS-01). The preclinical pipeline includes RVU305, a brain-permeable MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, alongside STING-based antibody-drug conjugates licensed to Exelixis and an emerging ADC payload program.

The company's discovery engine rests on two proprietary platforms: ONCO Prime, which integrates patient-derived models, engineered systems and high-throughput CRISPR/omics analytics with machine learning to identify synthetic-lethal vulnerabilities in genetically stratified cancers; and PERO, which performs functional validation of structural protein pockets to support rational drug design. A team of roughly 230 employees including 90 PhD holders, supported by an international patent portfolio covering CDK8, MELK, A2A/A2B adenosine receptor and STING agonist chemistries, underwrites the R&D base.

Ryvu is pre-commercial and does not generate product revenue. Operating revenues of EUR 20.7M in FY2025 and EUR 5.1M in Q1 2026 consist of research collaboration reimbursements, clinical milestone payments and non-dilutive grants from European institutions including the European Investment Bank, the Medical Research Agency (ABM), the National Centre for Research and Development (NCBR) and EU regional funds. Strategic commercialization is structured around out-licensing and co-development with major pharma partners — BioNTech (research collaboration extended to November 2028), Exelixis (STING ADCs) and Menarini Group (dapolsertib) — with potential for direct sales upon regulatory approval of romaciclib or other wholly-owned assets.

Name

Ryvu

Legal name

Ryvu Therapeutics S.A.

Website

https://ryvu.com/

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small molecule oncology therapies targeting CDK8/19, PIM/FLT3, and PRMT5. Headquartered in Kraków, Poland, it serves patients with hematologic malignancies and solid tumors through wholly-owned and partnered clinical programs.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Oncology drug development
• Small molecule therapies
• Clinical-stage biotechnology
• Hematologic malignancies
• Precision oncology

Headquarters

HQ city

Krakow

HQ country

Poland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Partnership Revenue: Ryvu generates revenue through research collaborations and licensing agreements with pharmaceutical partners including BioNTech, Exelixis, and Menarini Group. Partners reimburse Ryvu for expenses and the company can receive multiple milestone payments.
2. Grant Funding: Non-dilutive funding from government agencies including European Investment Bank (EUR 22 million venture debt), National Centre for Research and Development (NCBR), Medical Research Agency (ABM), and European Union regional funds. Q1 2026: EUR 5.1 million operating revenues including grants.
3. Clinical Milestones: Revenue recognition from milestones achieved in clinical programs and collaborations, including RVU120 Phase II progress triggering EIB funding disbursement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Ryvu Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel small molecule therapies targeting emerging oncology pathways, including CDK8/19, PIM/FLT3, and PRMT5. Its pipeline focuses on hematologic malignancies and selected solid tumors, with drug candidates advancing through preclinical and clinical stages (Phases 1 and 2). The company leverages proprietary discovery platforms to identify first-in-class therapeutic candidates for partnering or further development.

Product overview

Ryvu Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of small molecule oncology therapies with diverse therapeutic mechanisms. The core clinical programs include romaciclib (RVU120), a first-in-class CDK8/19 inhibitor with multiple Phase II trials in hematologic malignancies (RIVER-81 for AML, POTAMI-61 for myelofibrosis, REMARK for LR-MDS), and dapolsertib (MEN1703), a dual PIM/FLT3 kinase inhibitor in Phase II for DLBCL. The preclinical pipeline features RVU305 (MTA-cooperative PRMT5 inhibitor) and early discovery programs in ADCs with novel payloads. Discovery capabilities include the ONCO Prime precision oncology platform for synthetic lethal target identification and the PERO platform for functional target validation.

Differentiator

Problem solved

Functional benefit

Brands

• ONCO Prime: Precision oncology discovery platform leveraging patient-driven models, engineered systems, and high-throughput CRISPR/omics analytics for identification of synthetic lethal targets in genetically stratified cancers
• PERO
• ADCraft

Products and services

• Romaciclib (RVU120)

Quantifiable outcome

• 43% CR/CRi rate in RIVER-81 study at recommended dose of 150mg QD romaciclib + venetoclax
• +4 more outcomes

Named customers5 records

Segments8 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core and minor.

• BioNTechcoreStrategic or Co-development Partner · 16 March 2026Research collaboration and exclusive license option agreement originally disclosed in November 2022. In March 2026, the collaboration was extended by one year until November 2028. In September 2025, the collaboration was expanded to support BioNTech in accelerating site activation and patient enrollment for priority oncology clinical programs in Poland including lung, breast, and colorectal cancers. Ryvu supports BioNTech's clinical trials and is reimbursed for expenses with potential for milestone payments.
• Children's Memorial Health InstituteminorStrategic or Co-development Partner · 1 September 2025Collaboration initiated September 2025 as part of MEDWAY project, an investigator-initiated Phase I clinical study evaluating romaciclib in combination with everolimus in children with recurrent or progressive medulloblastoma. First patient first visit expected Q2 2026.
• Menarini GroupcoreStrategic or Co-development Partner · 26 March 2025JASPIS-01 Phase II study of dapolsertib (MEN1703/SEL24) for r/r DLBCL is fully funded by Menarini Group and operationally executed by Ryvu. First patient dosed March 2025.
• ExelixiscoreOEM/ Whitelabel/ Licensing Partner · 28 September 2022Exclusive license agreement with Exelixis for STING ADC technology. Ryvu develops STING-based antibody-drug conjugates for targeted cancer therapy under this partnership.
• EMSCOminorStrategic or Co-development PartnerPartnership for REMARK study - Phase II investigator-initiated trial of romaciclib in low-risk MDS. EMSCO provides funding and operational support.
• BCUnitedminorStrategic or Co-development PartnerPartnership for RIVER-81 study in relapsed/refractory AML. BCUnited provides funding and operational support for clinical development.

Scale indicators16 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Werewolf Therapeutics: US clinical-stage oncology biotech developing conditionally activated therapeutics. Comparable as a small-cap clinical-stage oncology company with platform-driven pipeline development.
• Bicycle Therapeutics: Clinical-stage UK biotech developing precision oncology therapeutics using bicyclic peptide technology. Comparable as a clinical-stage oncology company advancing novel modalities toward Phase II readouts with partnership revenue.
• Foghorn Therapeutics: US clinical-stage oncology biotech targeting chromatin regulatory biology with small molecules. Comparable to Ryvu's transcriptional regulation focus and similar Phase II-stage portfolio profile.
• Syros Pharmaceuticals: US clinical-stage precision oncology biotech using gene regulation platforms to develop small molecule therapies. Comparable in targeting transcriptional dysregulation and hematologic/oncology indications.
• Tempest Therapeutics: US clinical-stage immuno-oncology biotech developing small molecule therapies. Comparable in scale, clinical stage, and oncology small molecule focus.
• Kronos Bio: US clinical-stage oncology biotech developing small molecule therapies targeting dysregulated transcription and cell signaling. Closely comparable to Ryvu's CDK8/19 transcriptional regulation approach and Phase II hematology focus.
• Aprea Therapeutics: US clinical-stage oncology biotech focused on small molecule therapeutics targeting DNA damage response and synthetic lethality. Directly comparable to Ryvu's synthetic lethality and DDR-adjacent pipeline.
• BerGenBio: Norway-headquartered clinical-stage oncology biotech developing selective kinase inhibitors in hematologic and solid tumors. Highly comparable to Ryvu in size, stage, and kinase-targeting approach.

Broad incumbents

• Schrödinger: US computational drug discovery platform serving multiple therapeutic areas including oncology. Broader and more established than Ryvu but relevant given overlapping computational/discovery approaches to small molecule design.

Emerging players

• Recursion Pharmaceuticals: US AI-enabled drug discovery company developing pipeline across oncology and rare diseases. Comparable as a technology-driven drug discovery company, though with broader scope and larger capital base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ryvutx
• YouTubeyoutube.com/channel/UC0Eey2yJqilc9xC7gYAPI4g
• Facebookfacebook.com/RyvuTx
• LinkedInlinkedin.com/company/ryvutherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ryvu